Update on the Treatment of Inflammatory Bowel Disease
DOI:
https://doi.org/10.52787/agl.v52i3.244Keywords:
Ulcerative colitis, Crohn’s disease, inflammatory bowel diseases, treatment, personalized therapy, therapeutic goalsAbstract
Inflammatory bowel diseases, including Crohn’s disease and Ulcerative Colitis, are chronic, progressive, immune-mediated diseases that have no cure until now. Inflammatory bowel disease can cause significant morbidity and lead to complications such as strictures, fistulas, surgery, infections, and cancer. Inflammatory bowel disease is highly heterogeneous, with severity ranging from mild to severe and symptoms ranging from mild to debilitating. Early diagnosis and prompt institution of treatment are the cornerstones for maximizing outcomes and improving quality of life. In the last decade, several new therapies with different mechanisms of action have been approved for the management of inflammatory bowel disease. Although the therapeutic arsenal is growing, a significant percentage of patients do not respond to the established treatments. Decisions about optimal drug therapy in inflammatory bowel disease are complex, with limited guidance on comparative efficacy and safety of different treatments, leading to considerable practice variability. Risk stratification of disease severity, based on prognostic factors, can help guide selection of first-line therapy. After starting appropriate therapy, it is important to confirm remission using objective end points (treat to target) with continued control of inflammation with adjustment of therapy (tight control). In this review we provide a physician-oriented overview of clinical management of ulcerative colitis and Crohn’s disease in adults.
References
-1. Peyrin-Biroulet L, Loftus EV Jr, Colombel J-F, Sandborn WJ. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010;105:289-97.
-2. Agrawal M, Spencer EA, Colombel J-F, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User’s Guide for Adult and Pediatric Gastroenterologists. Gastroenterology. 2021;47-65. doi: 10.1053/j.gastro.2021.04.063
-3. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, et al. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016;14:348-54.e17.
-4. Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV Jr, et al. Development of an index to define overall disease severity in IBD. Gut. 2018;67:244-54.
-5. Torres J, Caprioli F, Katsanos KH, Lobatón T, Micic D, Zerôncio M, et al. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016;10:1385-94.
-6. Kiss LS, Papp M, Lovasz BD, Vegh Z, Golovics PA, Janka E, et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn’s disease: a marker for patient classification? Inflamm Bowel Dis. 2012;18:1647-54.
-7. Beaugerie L, Sokol H. Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol. 2012;18:3806-13.
-8. Mao R, Xiao Y-L, Gao X, Chen B-L, He Y, Yang L, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18:1894-99.
-9. Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015;42:391-405.
-10. Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative Colitis Care Pathway. Gastroenterology. 2015;149:238-45.
-11. Etchevers MJ, Aceituno M, García-Bosch O, Ordás I, Sans M, Ricart E, et al. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis. 2009;15:1320-5.
-12. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015;110:1324-38.
-13. Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;1570-83. doi: 10.1053/j.gastro.2020.12.031
-14. Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F. Guía GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodología GRADE. Gastroenterología y Hepatología. 2020;43:1-57.
-15. Satsangi J, Silverberg MS, Vermeire S, Colombel J-F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-53.
-16. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. The Lancet. 2012;1606-19. doi: 10.1016/S0140-6736(12)60150-0
-17. Tripathi K, Dong J, Mishkin BF, Feuerstein JD. Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis. Clin Exp Gastroenterol. 2021;14:343-51.
-18. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. Disponible en: https://academic.oup.com/ecco-jcc/article-abstract/2/1/1/443275
-19. Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-Planella E, et al. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el uso de tiopurinas en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología. 2018;41:205-21.
-20. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485-9.
-21. Laredo V, Gargallo-Puyuelo CJ, Gomollón F. How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease. J Clin Med Res. 2022;11. doi:10.3390/jcm11030829
-22. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel J-F, Törüner M, et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019;381:1215-26.
-23. Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158:1450-61.
-24. Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022;16:2-17.
-25. Singh S, Andersen NN, Andersson M, Loftus EV Jr, Jess T. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients with Ulcerative Colitis: A Nationwide Danish Cohort Study. Clin Gastroenterol Hepatol. 2017;15:1218-25.e7.
-26. Aseni P, De Carlis L, Mazzola A, Grande AM. Operative Techniques and Recent Advances in Acute Care and Emergency Surgery. Springer. 2019.
-27. Nguyen NH, Singh S, Sandborn WJ. Positioning Therapies in the Management of Crohn’s Disease. Clin Gastroenterol Hepatol. 2020;18:1268-79.
-28. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. American Journal of Gastroenterology. 2018;481-517. doi:10.1038/ajg.2018.27
-29. Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. J Crohns Colitis. 2020;14:4-22.
-30. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661-73.
-31. Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;CD006792.
-32. Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database of Systematic Reviews. 2016. doi: 10.1002/14651858.CD000545.pub5
-33. Patel V, Wang Y, MacDonald JK, McDonald JWD, Chande N. Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;CD006884.
-34. Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohns Colitis. 2013;7:213-21.
-35. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383-95.
-36. D’Haens GR, Panaccione R, Higgins PDR, Vermeire S, Gas-sull M, Chowers Y, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn’s and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? American Journal of Gastroenterology. 2011;199-212. doi: 10.1038/ajg.2010.392
-37. Paredes JM, Moreno-Osset E. Manejo práctico de la intensificación del tratamiento biológico en los pacientes con enfermedad inflamatoria intestinal. Enfermedad Inflamatoria Intestinal al Día. 2016;96-103. https://doi.org/10.1016/j.eii.2016.04.004
-38. Chaparro M, Gisbert JP. Nuevas moléculas en el tratamiento de la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología. 2016;411-23. https://doi.org/10.1016/j.gastrohep.2015.09.017
-39. Sands BE, Irving PM, Hoops T, Izanec JL, Gao L-L, Gasink C, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399:2200-11.
-40. Shmidt E, Ho EY, Feuerstein JD, Singh S, Terdiman JP. Spotlight: Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology. 2021;160:2511.
-41. Chaparro M, Gisbert JP. Actualización del diagnóstico y trat-amiento de la enfermedad de Crohn. Medicine - Programa de Formación Médica Continuada Acreditado. 2016;217-26. DOI: 10.1016/j.med.2016.02.018
-42. Bemelman WA, Allez M. The surgical intervention: Earlier or never? Best Practice & Research Clinical Gastroenterology. 2014;497-503. doi: 10.1016/j.bpg.2014.04.013
-43. Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2017;2:785-92.
-44. Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn’s disease complicated by strictures: a systematic review. Gut. 2013;62:1072-84.
-45. Vrabie R, Irwin GL, Friedel D. Endoscopic management of inflammatory bowel disease strictures. World J Gastrointest Endosc. 2012;4:500-5.
-46. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. Journal of Crohn’s and Colitis. 2010;28-62. doi:10.1016/j.crohns.2009.12.002
-47. Sánchez, Rodríguez. Tratamiento médico versus quirúrgico en la estenosis ileal como debut de enfermedad de Crohn estenosante. Rev Andal Med Deport. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=6758902
-48. Groof EJ de, Carbonnel F, Buskens CJ, Bemelman WA. Abdominal Abscess in Crohn’s Disease: Multidisciplinary Management. Digestive Diseases. 2014;103-9. doi: 10.1159/000367859
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 María Eugenia Linares, Claudia Fuxman, Maricel Bellicoso
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
